SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 188 filers reported holding SANGAMO THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $336 | -68.0% | 559,731 | -30.6% | 0.03% | -72.4% |
| Q2 2023 | $1,049 | +171.8% | 806,954 | +268.3% | 0.10% | +176.3% |
| Q1 2023 | $386 | -38.6% | 219,088 | +9.3% | 0.04% | -51.3% |
| Q4 2022 | $629 | -99.2% | 200,465 | +1232.0% | 0.08% | +680.0% |
| Q3 2022 | $74,000 | -21.3% | 15,050 | -33.9% | 0.01% | -28.6% |
| Q2 2022 | $94,000 | -55.0% | 22,785 | -36.7% | 0.01% | -50.0% |
| Q1 2022 | $209,000 | -27.9% | 35,978 | +11.6% | 0.03% | -6.7% |
| Q3 2021 | $290,000 | +215.2% | 32,240 | +215.4% | 0.03% | -41.2% |
| Q2 2020 | $92,000 | +8.2% | 10,223 | +0.3% | 0.05% | +410.0% |
| Q4 2019 | $85,000 | -86.3% | 10,189 | -84.3% | 0.01% | -84.1% |
| Q1 2019 | $620,000 | -31.3% | 65,031 | -17.3% | 0.06% | -39.4% |
| Q4 2018 | $902,000 | +104.5% | 78,600 | +238.5% | 0.10% | +352.2% |
| Q1 2018 | $441,000 | -55.8% | 23,221 | -63.5% | 0.02% | -42.5% |
| Q1 2015 | $997,000 | +261.2% | 63,576 | +316.9% | 0.04% | +100.0% |
| Q1 2014 | $276,000 | – | 15,249 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alexandria Capital, LLC | 1,003,725 | $15,663,000 | 1.66% |
| Golden State Equity Partners | 123,817 | $1,932,000 | 1.33% |
| Rhenman & Partners Asset Management AB | 821,888 | $12,826,000 | 1.05% |
| WASATCH ADVISORS LP | 10,072,381 | $157,180,000 | 0.77% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 29,636 | $462,000 | 0.73% |
| Ceeto Capital Group, LLC | 80,000 | $1,248,000 | 0.63% |
| EMC Capital Management | 48,992 | $765,000 | 0.58% |
| Fort Sheridan Advisors LLC | 71,173 | $1,111,000 | 0.54% |
| Vanguard Capital Wealth Advisors | 34,680 | $584,000 | 0.54% |
| Casdin Capital, LLC | 1,080,000 | $16,853,000 | 0.50% |